Lumos Pharma Inc (NAS:LUMO)
$ 3.94 0.1 (2.6%) Market Cap: 32.01 Mil Enterprise Value: 14.68 Mil PE Ratio: 0 PB Ratio: 3.10 GF Score: 47/100

Lumos Pharma Inc Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study-Corporate Call Transcript

Apr 27, 2021 / 02:30PM GMT
Release Date Price: $12.59 (-4.55%)
Operator

Good morning, and welcome to the Lumos Pharma KOL webinar on LUM-201 for the treatment of pediatric growth hormone deficiency. (Operator Instructions) As a reminder, this conference is being recorded, and a replay will be made available on the Lumos Pharma website following the event.

I would now like to turn the call over to your host, Rick Hawkins, Chief Executive Officer of Lumos Pharma. Please go ahead, Rick.

Richard J. Hawkins
Lumos Pharma, Inc. - Founder, Chairman, CEO & President

Good morning, and thank you for joining us for our KOL event on pediatric growth hormone deficiency in LUM-201, Lumos Pharma's therapeutic candidate targeting PGHD. I'm Rick Hawkins, CEO, Chairman, President of Lumos Pharma. I'll be joined by 2 noted thought leaders in the field of pediatric endocrinology for our discussion.

Before we proceed with our program, I'd like to remind everyone that certain statements made during this event are considered forward-looking statements under U.S. federal securities laws. Actual results may differ materially from the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot